Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF - Get Free Report)'s share price reached a new 52-week high during trading on Monday . The stock traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares traded. The stock had previously closed at $52.25.
Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a "hold" rating in a research report on Monday, October 7th.
Check Out Our Latest Stock Analysis on RCDTF
The firm has a market cap of $10.78 billion, a PE ratio of 26.13 and a beta of 0.33. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.73. The stock's 50 day moving average price is $52.25 and its 200 day moving average price is $51.86.
Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share for the quarter. The business had revenue of $622.00 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Recordati Industria Chimica e Farmaceutica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recordati Industria Chimica e Farmaceutica wasn't on the list.
While Recordati Industria Chimica e Farmaceutica currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.